Vulvovaginal discharge complaints are very common, accounting for more than 10 million U.S. office visits annually and countless phone contacts [1]. Annual medication costs for these complaints are estimated at more than $700 million, with about half this amount spent on overthe-counter (OTC) preparations [2]. The diagnosis of initial vulvovaginal discharge complaints is usually straightforward...

Vulvovaginal candidiasis is the second most common cause of vaginitis after bacterial vaginosis with at least 75 – 80% women have had one episode VVC in their lifetime. Their prevalent resistance to commonly used antifungal agents makes treatment a challenge physicians. Flavonoids been shown possess potent anti-Candida properties which can inhibit growth and proliferation Candida species throug...

Vulvovaginal candidiasis (VVC) is a commonly encountered clinical condition. At least three-fourth women experience one episode of VVC in their lifetime. In India, the prevalence 10 to 35%. Laboratory methods often supplement diagnosis. should be confirmed with culture and other investigative techniques, especially complicated recurrent cases. Topical intravaginal azoles remain mainstay therapy...